Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Signal Transduction and Targeted Therapy|October 15, 2025
Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patientsYin Yang, Yuqi Wu, Jingjing Zhao, et al.Signal Transduction and Targeted Therapy|October 4, 2022
Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancerYanhua Tian, Qingqing Li, Zhenlin Yang, et al.Ebiomedicine|July 28, 2022
Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancerYing Zuo, Jia Zhong, Hua Bai, et al.Ebiomedicine|January 14, 2025
ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A∗0201Li Yuan, Sini Li, Yixiang Zhu, et al.Science China. Life Sciences|May 17, 2026
Structure-based classification for differential tyrosine kinase inhibitors efficacy of EGFR exon 19 deletions in non-small cell lung cancerWei Zhuang, Hua Bai, Jie Zhao, et al.Cancer Cell|October 24, 2025
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 studyJia Zhong, Lin Wu, Zhengbo Song, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2019
Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 InhibitorsZhijie Wang, Jianchun Duan, Guoqiang Wang, et al.The Lancet. Respiratory Medicine|December 1, 2025
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trialJia Zhong, Jun Zhao, Jianchun Duan, et al.Signal Transduction and Targeted Therapy|December 23, 2024
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trialJia Zhong, Kailun Fei, Lin Wu, et al.Pageof 4